Table 1.

Eligibility criteria for clinical studies used in the systematic literature review

Eligibility criteria	Included	Excluded
Population	Adults (18+ years) with ND-CKD, with or without SHPT	Pediatric patients Patients on dialysis Patients who have undergone parathyroidectomy
Interventions/comparators	Any pharmacological intervention or combination of interventions commonly used for the treatment of SHPT or adjustment of SHPT-relevant biomarkers, specifically: nutritional vitamin D (NVD) supplementation cholecalciferol ergocalciferol calcitriol (the active form of vitamin D) vitamin D receptor activators (VDRA)/active vitamin D analogues alfacalcidol paricalcitol doxercalciferol calcifediol extended-release (PR) calcifediol immediate-release (IR) calcifediol (referred to as calcifediol in this report) calcimimetic cinacalcet	Non-pharmacological therapies eg, surgery, dietary
Outcomes	Treatment-specific efficacy/effectiveness Changes in biomarker levels from baseline; PTH, vitamin D metabolites (25(OH)D and 1,25(OH)2D), Calcium, Phosphate, FGF23 Treatment-specific outcomes Hypercalcemia, hyperphosphatemia, CV event, fracture, mortality, CKD progression, hospitalization, anemia, reduced BMD, parathyroidectomy
Study design	Comparative RCT	Comparative CCT, comparative observational studies, case studies, case reports, economic evaluations, reviews, meta-analyses
Other eligibility criteria	Studies of patients with ≥20 patients English language only Publication year: any year (until date of search: May 31, 2022)

Abbreviations: 1,25(OH)2D, 1,25-dihydroxyvitamin D; 25(OH)D, 25-hydroxyvitamin D; BMD, bone mineral density; CKD, chronic kidney disease; FGF23, fibroblast growth factor 23; ND-CKD, non-dialysis chronic kidney disease; PTH, parathyroid hormone; RCT, randomized controlled trial; SHPT, secondary hyperparathyroidism.